文献速递慢性肾脏病遗传性与小管间质肾病

CKD筛查:尿白蛋白还是uDKK3还是两者都用?

CKD screening: urinary albumin or uDKK3 or both?
PubMed 文献 · Nephrol Dial Transplant · 2026-08-05

本文讨论慢性肾脏病(CKD)筛查中尿白蛋白的局限性,指出非白蛋白尿性CKD因肾小管间质损伤而进展。尿Dickkopf-3(uDKK3)作为反映肾小管损伤与纤维化的新型生物标志物,在调整白蛋白尿等危险因素后仍能改善进展性CKD的检测与预测,尤其适用于非白蛋白尿人群。文章提出将白蛋白尿与uDKK3等肾小管标志物整合入未来CKD筛查策略的框架。

要点

  • CKD诊断依赖eGFR与白蛋白尿,但主要反映肾小球损伤,非白蛋白尿性CKD易漏诊。
  • uDKK3由近端小管上皮细胞在损伤时表达并分泌入尿,反映肾内纤维化活动。
  • 在调整白蛋白尿等危险因素后,uDKK3升高可显著改善进展性CKD的检测与预测。

核心结论

  • 尿白蛋白筛查存在局限性,非白蛋白尿性CKD因肾小管间质损伤而进展且初期难以检出。
  • uDKK3是反映肾小管损伤与纤维化的新型生物标志物,在调整白蛋白尿等危险因素后仍能改善进展性CKD的检测与预测。
  • 白蛋白尿与uDKK3反映肾脏损伤的不同生物学维度,可互补用于CKD筛查。

研究设计与样本

  • 本文为综述/评论,讨论白蛋白尿筛查的局限性并提出将肾小管标志物如uDKK3整合入未来CKD筛查策略的框架。
  • 文中引用临床研究覆盖广泛CKD病因的成人与儿童,以及以非白蛋白尿为主的人群(如2型糖尿病、心脏或肺部疾病患者)。

主要发现

  • 相当比例患者虽无显著白蛋白尿,但肾小管间质损伤持续导致肾功能恶化,即非白蛋白尿性CKD。
  • 在多项不同病因CKD的临床研究中,调整包括白蛋白尿在内的既定CKD风险标志物后,uDKK3升高显著改善进展性CKD的检测与预测。
  • 在非白蛋白尿为主的人群(如2型糖尿病、心脏或肺部疾病患者)中,uDKK3可识别未来肾功能下降的高危个体。

临床怎么用

  • 对CKD高危人群筛查时,除白蛋白尿外可考虑纳入uDKK3以识别非白蛋白尿性CKD高风险个体。
  • 白蛋白尿与uDKK3互补反映肾小球与肾小管间质损伤,可辅助分层评估进展风险。

局限性

  • uDKK3作为筛查标志物的标准化检测方法、阈值及成本效益尚未明确。
  • 将uDKK3整合入CKD筛查策略的框架仍需前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Approximately 750 million people worldwide suffer from chronic kidney diseases (CKD)-a leading cause of cardiovascular morbidity and premature mortality-but early identification of progressive kidney function decline in patients at risk is still a challenge. CKD diagnosis relies on estimated glomerular filtration rate (eGFR) and albuminuria screening, primarily reflecting glomerular injury. Nevertheless, in a substantial proportion of affected subjects progressive CKD initially remains undetected, since kidney function deteriorates through ongoing tubulointerstitial injury without significant albuminuria, a condition known as 'non-albuminuric' CKD. Urinary Dickkopf-3 (uDKK3) has emerged as an innovative biomarker of progressive CKD, which is expressed by proximal tubular epithelial cells as a response to continuing injury. It is secreted into the urine, where it signals ongoing fibrogenic activity within the kidney. Clinical studies across a broad range of CKD etiologies-in adults and children alike-have shown that elevated uDKK3 significantly improved detection and prediction of progressive CKD after adjustment for established CKD risk markers including albuminuria. Moreover, in primarily non-albuminuric populations, e.g. those with type 2 diabetes and patients with heart or lung diseases, uDKK3 identifies high-risk individuals for future decline of kidney function. These findings support the hypothesis that CKD progression follows different pathways of mainly glomerular or tubulointerstitial injury. It is therefore plausible to use complementary biomarkers for CKD screening-albuminuria and uDKK3-each reflecting a distinct biological dimension of kidney injury. We discuss the limitations of albuminuria screening and propose a framework for integrating tubular markers like uDKK3 into future CKD screening strategies.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Neuhaus S, Fliser D, Schunk S, et al. CKD screening: urinary albumin or uDKK3 or both? Nephrol Dial Transplant. 2026. PMID: 42554977. doi:10.1093/ndt/gfag166

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。